A Pragmatic Eight-Week Phase IV Study of Bamlanivimab/LY-CoV555 for Emergency Passive Immunity Against COVID-19.
Bamlanivimab is designed to block the COVID -19 virus from attaching to, entering, and infecting human cells. Health Canada has authorized the emergency use of this medication for COVID-19 but we need more information about its safety and efficacy before it can be widely used.
COVID-19 can be difficult to treat. Studies are underway to determine if medications, including bamlanivimab, can reduce hospital stays and serious illness in people with COVID-19.
Participants will receive either standard of care or bamlanivimab, given as a one-time intravenous infusion in a COVID-19 clinic. Participants must test positive for COVID-19, be over 18 years of age, and meet other medical criteria for being high-risk for moderate or severe COVID-19.
UPDATE May 10, 2021: The study treatment phase is complete. Bamlanivimab is no longer being offered to participants. However, new participants are still being enrolled and provided with standard medical care for their COVID-19 infection.
The study is currently recruiting controls, and we need as many COVID-positive patients as possible!